|Protalex, Inc. is a development-stage company, which has been engaged in developing a class of biopharmaceutical drugs for treating autoimmune inflammatory diseases. The Company’s lead product PRTX-100, is formulated with staphylococcal protein A, which is an immune modulating protein produced by bacteria. As of May 31, 2012, the Company does not have any products on the market and does not anticipate generating operating revenue for the foreseeable future. PRTX-100 is a form of the Staphylococcal bacterial protein known as Protein A. PRTX-100 has the ability, at low concentrations, to bind to and to down regulate activation of human B-lymphocytes and macrophages, which are the cells mediating inflammation in certain autoimmune diseases.|
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.